Detalles de la búsqueda
1.
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Ann Oncol
; 32(8): 1005-1014, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33932503
2.
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Ann Oncol
; 30(8): 1279-1288, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31095287
3.
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Ann Oncol
; 29(1): 178-185, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29069370
4.
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Ann Oncol
; 29(12): 2341-2347, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335131
5.
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat
; 168(1): 179-187, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177689
6.
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Ann Oncol
; 28(8): 1803-1810, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28459941
7.
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Ann Oncol
; 33(7): 743-744, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35595658
8.
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Ann Oncol
; 28(3): 497-504, 2017 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27831502
9.
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Breast Cancer Res Treat
; 166(3): 775-785, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28822007
10.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Ann Oncol
; 27(8): 1519-25, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27177864
11.
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Ann Oncol
; 27(11): 2053-2059, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502721
12.
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Ann Oncol
; 27(11): 2046-2052, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502725
13.
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Ann Oncol
; 27(6): 1029-1034, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26961151
14.
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Ann Oncol
; 26(7): 1280-91, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26019189
15.
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
Ann Oncol
; 26(1): 95-100, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355716
16.
The AURORA initiative for metastatic breast cancer.
Br J Cancer
; 111(10): 1881-7, 2014 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25225904
17.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Ann Oncol
; 30(7): 1180, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30624609
18.
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Ann Oncol
; 25(1): 81-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24273046
19.
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.
Ann Oncol
; 25(4): 773-780, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24351401
20.
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto).
Ann Oncol
; 25(12): 2363-2372, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25223482